StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $9.84 | $9.90 | +0.61% | 0.7M |
| 05-12 | $9.70 | $9.79 | +0.93% | 0.4M |
| 05-13 | $9.76 | $9.97 | +2.15% | 0.4M |
| 05-14 | $9.98 | $9.95 | -0.30% | 0.9M |
| 05-15 | $9.88 | $9.40 | -4.86% | 0.8M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for MGTX.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for MGTX.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
| Metric | Q3 2023 2023-09-30 | Q2 2023 2023-06-30 | Q1 2023 2023-03-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $11.98M | $6.87M | $3.33M | $15.92M |
Operating Income | $-93.31M | $-60.55M | $-31.76M | $-116.36M |
Net Income | $-104.24M | $-29.58M | $-30.36M | $-129.62M |
EPS (Diluted) | $-1.91 | $-1.15 | $-0.62 | $-2.87 |
Total Assets | $267.19M | $310.26M | $288.14M | $318.24M |
Total Liabilities | $175.31M | $186.74M | $197.92M | $200.50M |
Cash & Equivalents | $63.37M | $92.77M | $68.78M | $115.52M |
Free Cash Flow OCF − CapEx | $-107.96M | $-79.98M | $-46.00M | $-118.06M |
Shares Outstanding | 59.60M | 59.54M | 48.48M | 48.48M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.